Volume | 1,031,697 |
|
|||||
News | - | ||||||
Day High | 44.21 | Low High |
|||||
Day Low | 43.12 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
44.08 | 43.12 | 44.21 | 43.15 | 43.84 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,710 | 1,031,697 | $ 43.51 | $ 44,889,725 | - | 31.05 - 45.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:29:39 | 22 | $ 43.15 | USD |
Halozyme Therapeutics (HALO) Options Flow Summary
Halozyme Therapeutics Incorporated Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.47B | 126.82M | - | 829.25M | 281.59M | 2.22 | 19.43 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Halozyme Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 40.67 | 44.785 | 39.79 | 41.80 | 1,345,372 | 1.89 | 4.65% |
1 Month | 39.00 | 44.785 | 37.73 | 39.83 | 911,869 | 3.56 | 9.13% |
3 Months | 35.72 | 44.785 | 35.44 | 40.04 | 1,026,708 | 6.84 | 19.15% |
6 Months | 36.94 | 44.785 | 33.15 | 38.03 | 1,166,148 | 5.62 | 15.21% |
1 Year | 32.13 | 45.00 | 31.05 | 37.92 | 1,078,643 | 10.43 | 32.46% |
3 Years | 47.14 | 59.46 | 29.85 | 41.05 | 1,103,033 | -4.58 | -9.72% |
5 Years | 16.19 | 59.46 | 12.71 | 34.91 | 1,200,517 | 26.37 | 162.88% |
Halozyme Therapeutics Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |